Male DCIS diagnosed after use of over-the-counter hormonal supplement

S O Agbroko; K E Rojas; D M Manasseh; P Borgen

doi:10.1016/j.ijscr.2019.02.028

Male DCIS diagnosed after use of over-the-counter hormonal supplement

Int J Surg Case Rep. 2019:57:60-62. doi: 10.1016/j.ijscr.2019.02.028. Epub 2019 Feb 26.

Authors

S O Agbroko¹, K E Rojas², D M Manasseh², P Borgen²

Affiliations

¹ Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn NY, United States. Electronic address: sagbroko@maimonidesmed.org.
² Department of Surgery, Maimonides Medical Center, Brooklyn NY, United States.

Abstract

Introduction: Male breast cancer is a rare disease. Although epidemiologic and genetic factors are associated with male breast cancer, hormonal factors may also play a role.

Case presentation: We report the case of a 39-year-old BRCA negative male patient taking a sexual performance enhancement supplement who presented with worsening asymmetric gynecomastia and unilateral spontaneous bloody nipple discharge and was found to have ductal carcinoma in-situ.

Discussion: The altered cellular environment related to the hormone contents of the supplement coincided with the rapid worsening of his gynecomastia and may have played a role in the development of the ductal carcinoma in-situ, or growth of an existing focus.

Conclusion: The use of hormonal male enhancement supplements can lead to higher levels of androgens in users. It is possible for this altered hormonal environment to cause the growth of tumor or promote the progression of an existing focus.

Keywords: Atypical ductal hyperplasia; Ductal carcinoma in-situ; Gynecomastia; Male breast cancer; Mastectomy.